BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci. 2007;1113:202-216. [PMID: 17513464 DOI: 10.1196/annals.1391.012] [Cited by in Crossref: 380] [Cited by in F6Publishing: 341] [Article Influence: 25.3] [Reference Citation Analysis]
Number Citing Articles
1 Trendowski M. PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction. Pharmacological Research 2015;99:202-16. [DOI: 10.1016/j.phrs.2015.06.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
2 Grant S. Enhancing proteotoxic stress as an anticancer strategy. Oncotarget 2011;2:284-6. [PMID: 21525531 DOI: 10.18632/oncotarget.268] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
3 Zoroquiain P, Faingold D, Algahmdi S, Vila N, Logan P, Sanft DM, Toledo Dias AB, Aldrees S, Bravo-Filho V, Burnier J, Burnier MN. Analysis of HSP90 Expression Is Valuable in the Differential Diagnosis of Ocular Surface Squamous Lesions. Am J Clin Pathol 2016;145:385-92. [PMID: 27124921 DOI: 10.1093/ajcp/aqw007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Tao H, Chen YY, Sun ZW, Chen HL, Chen M. Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90. J Cell Biochem. 2018;119:6623-6632. [PMID: 29665050 DOI: 10.1002/jcb.26841] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
5 Ono K, Eguchi T, Sogawa C, Calderwood SK, Futagawa J, Kasai T, Seno M, Okamoto K, Sasaki A, Kozaki KI. HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. J Cell Biochem 2018;119:7350-62. [PMID: 29768689 DOI: 10.1002/jcb.27039] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 14.8] [Reference Citation Analysis]
6 Tokui K, Adachi H, Waza M, Katsuno M, Minamiyama M, Doi H, Tanaka K, Hamazaki J, Murata S, Tanaka F, Sobue G. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 2009;18:898-910. [PMID: 19066230 DOI: 10.1093/hmg/ddn419] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 5.7] [Reference Citation Analysis]
7 Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, Judson I, Workman P, Eisen T. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs 2012;30:341-9. [PMID: 20683637 DOI: 10.1007/s10637-010-9493-4] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
8 Li L, Wang L, You Q, Xu X. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions. J Med Chem 2020;63:1798-822. [DOI: 10.1021/acs.jmedchem.9b00940] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
9 Rodrigues LM, Chung YL, Al Saffar NM, Sharp SY, Jackson LE, Banerji U, Stubbs M, Leach MO, Griffiths JR, Workman P. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy. BMC Res Notes 2012;5:250. [PMID: 22621282 DOI: 10.1186/1756-0500-5-250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
10 Liang C, Wu X, Li Z, Zhu J, Lu C, Shen Y. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors. European Journal of Medicinal Chemistry 2018;143:85-96. [DOI: 10.1016/j.ejmech.2017.11.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Zagouri F, Sergentanis TN, Nonni A, Papadimitriou CA, Michalopoulos NV, Domeyer P, Theodoropoulos G, Lazaris A, Patsouris E, Zogafos E, Pazaiti A, Zografos GC. Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions. BMC Cancer 2010;10:353. [PMID: 20602789 DOI: 10.1186/1471-2407-10-353] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
12 Zuehlke AD, Moses MA, Neckers L. Heat shock protein 90: its inhibition and function. Philos Trans R Soc Lond B Biol Sci 2018;373:20160527. [PMID: 29203712 DOI: 10.1098/rstb.2016.0527] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
13 Husain H, Waseem M, Ahmad R. Proteomic and molecular evidences of Il1rl2, Ric8a, Krt18 and Hsp90b1 modulation during experimental hepatic fibrosis and pomegranate supplementation. Int J Biol Macromol 2021;185:696-707. [PMID: 34174316 DOI: 10.1016/j.ijbiomac.2021.06.091] [Reference Citation Analysis]
14 Barluenga S, Fontaine JG, Wang C, Aouadi K, Chen R, Beebe K, Neckers L, Winssinger N. Inhibition of HSP90 with pochoximes: SAR and structure-based insights. Chembiochem 2009;10:2753-9. [PMID: 19856365 DOI: 10.1002/cbic.200900494] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
15 Luo W, Rodina A, Chiosis G. Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? BMC Neurosci 2008;9 Suppl 2:S7. [PMID: 19090995 DOI: 10.1186/1471-2202-9-S2-S7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
16 Liang C, Hao H, Wu X, Li Z, Zhu J, Lu C, Shen Y. Design and synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors. European Journal of Medicinal Chemistry 2016;121:272-82. [DOI: 10.1016/j.ejmech.2016.05.033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
17 Centenera MM, Carter SL, Gillis JL, Marrocco-tallarigo DL, Grose RH, Tilley WD, Butler LM. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer 2015;22:805-18. [DOI: 10.1530/erc-14-0541] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
18 Horibe T, Torisawa A, Kohno M, Kawakami K. Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide. BMC Cancer 2014;14:615. [PMID: 25159299 DOI: 10.1186/1471-2407-14-615] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
19 Li Y, Karagöz GE, Seo YH, Zhang T, Jiang Y, Yu Y, Duarte AM, Schwartz SJ, Boelens R, Carroll K, Rüdiger SG, Sun D. Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90. J Nutr Biochem 2012;23:1617-26. [PMID: 22444872 DOI: 10.1016/j.jnutbio.2011.11.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
20 Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008;51:196-218. [PMID: 18020435 DOI: 10.1021/jm701018h] [Cited by in Crossref: 311] [Cited by in F6Publishing: 276] [Article Influence: 20.7] [Reference Citation Analysis]
21 Lacey T, Lacey H. Linking hsp90's role as an evolutionary capacitator to the development of cancer. Cancer Treat Res Commun 2021;28:100400. [PMID: 34023771 DOI: 10.1016/j.ctarc.2021.100400] [Reference Citation Analysis]
22 Sangeetha M, Mathammal R. Structure-activity relationship of the ionic cocrystal: 5-amino-2-naphthalene sulfonate·ammonium ions for pharmaceutical applications. Journal of Molecular Structure 2018;1154:327-37. [DOI: 10.1016/j.molstruc.2017.10.060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
23 Hombach A, Clos J. No stress--Hsp90 and signal transduction in Leishmania. Parasitology 2014;141:1156-66. [PMID: 24703183 DOI: 10.1017/S0031182013002151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
24 Emde A, Köstler WJ, Yarden Y; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol 2012;84 Suppl 1:e49-57. [PMID: 20951604 DOI: 10.1016/j.critrevonc.2010.09.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
25 Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A, Cippitelli M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol 2009;183:4385-94. [PMID: 19748980 DOI: 10.4049/jimmunol.0901797] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
26 Hafeez U, Parslow AC, Gan HK, Scott AM. New insights into ErbB3 function and therapeutic targeting in cancer. Expert Rev Anticancer Ther 2020;20:1057-74. [PMID: 32981377 DOI: 10.1080/14737140.2020.1829485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 2013;39:375-87. [PMID: 23199899 DOI: 10.1016/j.ctrv.2012.10.001] [Cited by in Crossref: 165] [Cited by in F6Publishing: 154] [Article Influence: 16.5] [Reference Citation Analysis]
28 Calderwood SK, Murshid A. Molecular Chaperone Accumulation in Cancer and Decrease in Alzheimer's Disease: The Potential Roles of HSF1. Front Neurosci 2017;11:192. [PMID: 28484363 DOI: 10.3389/fnins.2017.00192] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
29 Moses MA, Henry EC, Ricke WA, Gasiewicz TA. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model. Cancer Prev Res (Phila) 2015;8:249-57. [PMID: 25604133 DOI: 10.1158/1940-6207.CAPR-14-0224] [Cited by in Crossref: 36] [Cited by in F6Publishing: 15] [Article Influence: 5.1] [Reference Citation Analysis]
30 Dabbs RA, Wyatt AR, Yerbury JJ, Ecroyd H, Wilson MR. Extracellular Chaperones. Top Curr Chem 2010. [PMID: 21516385 DOI: 10.1007/128_2010_85] [Reference Citation Analysis]
31 Zhao J, Zhao H, Hall JA, Brown D, Brandes E, Bazzill J, Grogan PT, Subramanian C, Vielhauer G, Cohen MS, Blagg BS. Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors. Medchemcomm 2014;5:1317-23. [PMID: 25328661 DOI: 10.1039/C4MD00102H] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
32 Kumar Mv V, Ebna Noor R, Davis RE, Zhang Z, Sipavicius E, Keramisanou D, Blagg BSJ, Gelis I. Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain. Medchemcomm 2018;9:1323-31. [PMID: 30151087 DOI: 10.1039/c8md00151k] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK, Yu X, Yan C, Chen X. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochem Pharmacol 2013;85:1246-56. [PMID: 23415900 DOI: 10.1016/j.bcp.2013.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
34 Mohammadian M, Zeynali S, Azarbaijani AF, Khadem Ansari MH, Kheradmand F. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines. Res Pharm Sci 2017;12:517-25. [PMID: 29204180 DOI: 10.4103/1735-5362.217432] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
35 Pennisi R, Ascenzi P, di Masi A. Hsp90: A New Player in DNA Repair? Biomolecules 2015;5:2589-618. [PMID: 26501335 DOI: 10.3390/biom5042589] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
36 Zagouri F, Sergentanis T, Nonni A, Papadimitriou C, Pazaiti A, Michalopoulos NV, Safioleas P, Lazaris A, Theodoropoulos G, Patsouris E, Zografos G. Decreased Hsp90 expression in infiltrative lobular carcinoma: an immunohistochemical study. BMC Cancer 2010;10:409. [PMID: 20691061 DOI: 10.1186/1471-2407-10-409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
37 Zhao H, Yan B, Peterson LB, Blagg BS. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. ACS Med Chem Lett 2012;3:327-31. [PMID: 23316269 DOI: 10.1021/ml300018e] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
38 Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, Workman P. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009;69:1966-75. [PMID: 19244114 DOI: 10.1158/0008-5472.CAN-08-3131] [Cited by in Crossref: 85] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
39 Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013;19:6020-6029. [PMID: 24045182 DOI: 10.1158/1078-0432.ccr-13-0953] [Cited by in Crossref: 50] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
40 Okoye FBC, Lu S, Nworu CS, Esimone CO, Proksch P, Chadli A, Debbab A. Depsidone and diaryl ether derivatives from the fungus Corynespora cassiicola, an endophyte of Gongronema latifolium. Tetrahedron Letters 2013;54:4210-4. [DOI: 10.1016/j.tetlet.2013.05.117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
41 Brock WJ, Somps CJ, Torti V, Render JA, Jamison J, Rivera MI. Ocular Toxicity Assessment From Systemically Administered Xenobiotics: Considerations in Drug Development. Int J Toxicol 2013;32:171-88. [DOI: 10.1177/1091581813484500] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
42 Van Drie JH. Protein folding, protein homeostasis, and cancer. Chin J Cancer 2011;30:124-37. [PMID: 21272445 DOI: 10.5732/cjc.010.10162] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
43 Karkoulis PK, Stravopodis DJ, Margaritis LH, Voutsinas GE. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer 2010;10:481. [PMID: 20828379 DOI: 10.1186/1471-2407-10-481] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
44 Smith JR, Workman P. Targeting the cancer chaperone HSP90. Drug Discovery Today: Therapeutic Strategies 2007;4:219-27. [DOI: 10.1016/j.ddstr.2008.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
45 Garcia J, Barluenga S, Beebe K, Neckers L, Winssinger N. Concise modular asymmetric synthesis of deguelin, tephrosin and investigation into their mode of action. Chemistry 2010;16:9767-71. [PMID: 20572190 DOI: 10.1002/chem.201001080] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
46 Birbo B, Madu EE, Madu CO, Jain A, Lu Y. Role of HSP90 in Cancer. Int J Mol Sci 2021;22:10317. [PMID: 34638658 DOI: 10.3390/ijms221910317] [Reference Citation Analysis]
47 Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Review of Neurotherapeutics 2014;9:519-34. [DOI: 10.1586/ern.09.10] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
48 McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat. 2008;11:164-179. [PMID: 18818117 DOI: 10.1016/j.drup.2008.08.002] [Cited by in Crossref: 211] [Cited by in F6Publishing: 201] [Article Influence: 15.1] [Reference Citation Analysis]
49 Mccleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 2009;125:2792-801. [DOI: 10.1002/ijc.24660] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
50 Chen X, Lu P, Wu Y, Wang D, Zhou S, Yang S, Shen H, Zhang X, Zhao J, Tang J. MiRNAs-mediated cisplatin resistance in breast cancer. Tumor Biol 2016;37:12905-13. [DOI: 10.1007/s13277-016-5216-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
51 Smith DF, Toft DO. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol. 2008;22:2229-2240. [PMID: 18451092 DOI: 10.1210/me.2008-0089] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 8.0] [Reference Citation Analysis]
52 Mcconkey DJ, White M, Yan W. HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer. Histone Deacetylase Inhibitors as Cancer Therapeutics. Elsevier; 2012. pp. 131-63. [DOI: 10.1016/b978-0-12-394387-3.00004-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
53 Terracciano S, Russo A, Chini MG, Vaccaro MC, Potenza M, Vassallo A, Riccio R, Bifulco G, Bruno I. Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain. Sci Rep 2018;8:1709. [PMID: 29374167 DOI: 10.1038/s41598-017-14902-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
54 Ochiana SO, Taldone T, Chiosis G. Designing Drugs Against Hsp90 for Cancer Therapy. In: Houry WA, editor. The Molecular Chaperones Interaction Networks in Protein Folding and Degradation. New York: Springer; 2014. pp. 151-83. [DOI: 10.1007/978-1-4939-1130-1_7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
55 Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene. 2010;29:325-334. [PMID: 19855434 DOI: 10.1038/onc.2009.337] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 6.7] [Reference Citation Analysis]
56 Robbins N, Collins C, Morhayim J, Cowen LE. Metabolic control of antifungal drug resistance. Fungal Genetics and Biology 2010;47:81-93. [DOI: 10.1016/j.fgb.2009.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
57 Liebscher S, Koi L, Löck S, Muders MH, Krause M. The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo. Clin Transl Radiat Oncol 2017;2:7-12. [PMID: 29657993 DOI: 10.1016/j.ctro.2016.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
58 Rowlands M, McAndrew C, Prodromou C, Pearl L, Kalusa A, Jones K, Workman P, Aherne W. Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using the TranscreenerTM ADP assay kit. J Biomol Screen 2010;15:279-86. [PMID: 20147598 DOI: 10.1177/1087057109360253] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
59 Lee CW, Kwon YC, Lee Y, Park MY, Choe KM. cdc37 is essential for JNK pathway activation and wound closure in Drosophila. Mol Biol Cell 2019;30:2651-8. [PMID: 31483695 DOI: 10.1091/mbc.E18-12-0822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
60 Arteaga CL. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer? Clin Cancer Res 2011;17:4919-21. [PMID: 21670086 DOI: 10.1158/1078-0432.CCR-11-1218] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
61 Jiang L, Yin R, Wang X, Dai J, Li J, Jiang T, Yu R. Design and synthesis of neolamellarin a derivatives targeting heat shock protein 90. Eur J Med Chem 2017;135:24-33. [PMID: 28426997 DOI: 10.1016/j.ejmech.2017.04.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
62 Armstrong HK, Gillis JL, Johnson IRD, Nassar ZD, Moldovan M, Levrier C, Sadowski MC, Chin MY, Tomlinson Guns ES, Tarulli G, Lynn DJ, Brooks DA, Selth LA, Centenera MM, Butler LM. Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. Sci Rep 2018;8:2090. [PMID: 29391407 DOI: 10.1038/s41598-018-19871-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
63 Eyermann CE, Haley JD, Alexandrova EM. The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer. Cell Death Dis 2021;12:126. [PMID: 33500390 DOI: 10.1038/s41419-021-03414-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Xu Y, Zhou T, Zhang S, Xuan LJ, Zhan J, Molnár I. Thioesterase domains of fungal nonreducing polyketide synthases act as decision gates during combinatorial biosynthesis. J Am Chem Soc 2013;135:10783-91. [PMID: 23822773 DOI: 10.1021/ja4041362] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
65 Audisio D, Messaoudi S, Cegielkowski L, Peyrat J, Brion J, Methy-gonnot D, Radanyi C, Renoir J, Alami M. Discovery and Biological Activity of 6BrCaQ as an Inhibitor of the Hsp90 Protein Folding Machinery. ChemMedChem 2011;6:804-15. [DOI: 10.1002/cmdc.201000489] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
66 Goode KM, Petrov DP, Vickman RE, Crist SA, Pascuzzi PE, Ratliff TL, Davisson VJ, Hazbun TR. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation. Biochim Biophys Acta Gen Subj 2017;1861:1992-2006. [PMID: 28495207 DOI: 10.1016/j.bbagen.2017.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
67 Au Q, Zhang Y, Barber JR, Ng SC, Zhang B. Identification of inhibitors of HSF1 functional activity by high-content target-based screening. J Biomol Screen 2009;14:1165-75. [PMID: 19820069 DOI: 10.1177/1087057109347472] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
68 Brancaleone V, Vellecco V, Matassa DS, d'Emmanuele di Villa Bianca R, Sorrentino R, Ianaro A, Bucci M, Esposito F, Cirino G. Crucial role of androgen receptor in vascular H2S biosynthesis induced by testosterone. Br J Pharmacol 2015;172:1505-15. [PMID: 24750035 DOI: 10.1111/bph.12740] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
69 Boschelli F, Golas JM, Petersen R, Lau V, Chen L, Tkach D, Zhao Q, Fruhling DS, Liu H, Nam C, Arndt KT. A cell-based screen for inhibitors of protein folding and degradation. Cell Stress Chaperones 2010;15:913-27. [PMID: 20717760 DOI: 10.1007/s12192-010-0200-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
70 Liu H, Lu J, Hua Y, Zhang P, Liang Z, Ruan L, Lian C, Shi H, Chen K, Tu Z. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Cell Death Dis. 2015;6:e1595. [PMID: 25590805 DOI: 10.1038/cddis.2014.555] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
71 Kim LS, Kim JH. Heat shock protein as molecular targets for breast cancer therapeutics. J Breast Cancer. 2011;14:167-174. [PMID: 22031796 DOI: 10.4048/jbc.2011.14.3.167] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
72 Horibe T, Kawamoto M, Kohno M, Kawakami K. Cytotoxic activity to acute myeloid leukemia cells by Antp-TPR hybrid peptide targeting Hsp90. J Biosci Bioeng 2012;114:96-103. [PMID: 22425524 DOI: 10.1016/j.jbiosc.2012.02.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
73 Ran F, Liu Y, Wang C, Xu Z, Zhang Y, Liu Y, Zhao G, Ling Y. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Eur J Med Chem 2021;:114009. [PMID: 34839996 DOI: 10.1016/j.ejmech.2021.114009] [Reference Citation Analysis]
74 Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823:742-755. [PMID: 22062686 DOI: 10.1016/j.bbamcr.2011.10.008] [Cited by in Crossref: 285] [Cited by in F6Publishing: 271] [Article Influence: 25.9] [Reference Citation Analysis]
75 Tonini G. Trends in the early investigational drug development and areas for improvement. Expert Opin Investig Drugs 2015;24:845-50. [PMID: 25891429 DOI: 10.1517/13543784.2015.1037881] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Bickel D, Gohlke H. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action. Bioorganic & Medicinal Chemistry 2019;27:115080. [DOI: 10.1016/j.bmc.2019.115080] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
77 Montanari P, Bozza G, Capecchi B, Caproni E, Barrile R, Norais N, Capitani M, Sallese M, Cecchini P, Ciucchi L, Gao Z, Rappuoli R, Pizza M, Aricò B, Merola M. Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)-mediated adhesion and invasion: Hsp90 hampers NadA-mediated infectivity. Cellular Microbiology 2012;14:368-85. [DOI: 10.1111/j.1462-5822.2011.01722.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
78 Vallée F, Carrez C, Pilorge F, Dupuy A, Parent A, Bertin L, Thompson F, Ferrari P, Fassy F, Lamberton A, Thomas A, Arrebola R, Guerif S, Rohaut A, Certal V, Ruxer JM, Gouyon T, Delorme C, Jouanen A, Dumas J, Grépin C, Combeau C, Goulaouic H, Dereu N, Mikol V, Mailliet P, Minoux H. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone. J Med Chem 2011;54:7206-19. [PMID: 21972823 DOI: 10.1021/jm200784m] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
79 Lawal B, Kuo YC, Wu ATH, Huang HS. BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase. Int J Biol Sci 2021;17:3224-38. [PMID: 34421361 DOI: 10.7150/ijbs.62808] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Cortajarena AL, Yi F, Regan L. Designed TPR modules as novel anticancer agents. ACS Chem Biol 2008;3:161-6. [PMID: 18355005 DOI: 10.1021/cb700260z] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 5.4] [Reference Citation Analysis]
81 Kim SH, Tangallapally R, Kim IC, Trovato R, Parker D, Patton JS, Reeves L, Bradford C, Wettstein D, Baichwal V, Papac D, Bajji A, Carlson R, Yager KM. Discovery of an L-alanine ester prodrug of the Hsp90 inhibitor, MPC-3100. Bioorg Med Chem Lett 2015;25:5254-7. [PMID: 26483201 DOI: 10.1016/j.bmcl.2015.09.053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
82 Park Y, Kubo A, Komiya T, Coxon A, Beebe K, Neckers L, Meltzer PS, Kaye FJ. Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras. Cell Cycle 2008;7:2384-91. [PMID: 18677112 DOI: 10.4161/cc.6363] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
83 Onodera H, Kaneko M, Takahashi Y, Uochi Y, Funahashi J, Nakashima T, Soga S, Suzuki M, Ikeda S, Yamashita Y, Rahayu ES, Kanda Y, Ichimura M. Conformational significance of EH21A1–A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity. Bioorganic & Medicinal Chemistry Letters 2008;18:1588-91. [DOI: 10.1016/j.bmcl.2008.01.072] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
84 Ishida R, Takaoka Y, Yamamoto S, Miyazaki T, Otaka M, Watanabe S, Komatsuda A, Wakui H, Sawada K, Kubota H, Itoh H. Cisplatin differently affects amino terminal and carboxyl terminal domains of HSP90. FEBS Lett 2008;582:3879-83. [PMID: 18955054 DOI: 10.1016/j.febslet.2008.10.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
85 Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs 2011;29:1206-12. [PMID: 20533075 DOI: 10.1007/s10637-010-9465-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
86 Steppan DA, Pratilas CA, Loeb DM. Targeted therapy for soft tissue sarcomas in adolescents and young adults. Adolesc Health Med Ther 2017;8:41-55. [PMID: 28408855 DOI: 10.2147/AHMT.S70377] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
87 Wang B, Chen Z, Yu F, Chen Q, Tian Y, Ma S, Wang T, Liu X. Hsp90 regulates autophagy and plays a role in cancer therapy. Tumor Biol 2016;37:1-6. [DOI: 10.1007/s13277-015-4142-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
88 Radanyi C, Le Bras G, Messaoudi S, Bouclier C, Peyrat JF, Brion JD, Marsaud V, Renoir JM, Alami M. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90). Bioorg Med Chem Lett 2008;18:2495-8. [PMID: 18304811 DOI: 10.1016/j.bmcl.2008.01.128] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
89 Lackie RE, Maciejewski A, Ostapchenko VG, Marques-Lopes J, Choy WY, Duennwald ML, Prado VF, Prado MAM. The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. Front Neurosci 2017;11:254. [PMID: 28559789 DOI: 10.3389/fnins.2017.00254] [Cited by in Crossref: 133] [Cited by in F6Publishing: 112] [Article Influence: 26.6] [Reference Citation Analysis]
90 Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, Burrows F, Zhang H. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 2010;15:31-8. [PMID: 19747088 DOI: 10.3109/13547500903261347] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
91 Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012;18:64-76. [PMID: 22215907 DOI: 10.1158/1078-0432.CCR-11-1000] [Cited by in Crossref: 667] [Cited by in F6Publishing: 391] [Article Influence: 66.7] [Reference Citation Analysis]
92 London CA, Bear MD, McCleese J, Foley KP, Paalangara R, Inoue T, Ying W, Barsoum J. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS One 2011;6:e27018. [PMID: 22073242 DOI: 10.1371/journal.pone.0027018] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
93 van Montfort RL, Workman P. Structure-based design of molecular cancer therapeutics. Trends Biotechnol 2009;27:315-28. [PMID: 19339067 DOI: 10.1016/j.tibtech.2009.02.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
94 Barluenga S, Wang C, Fontaine JG, Aouadi K, Beebe K, Tsutsumi S, Neckers L, Winssinger N. Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor. Angew Chem Int Ed Engl 2008;47:4432-5. [PMID: 18435518 DOI: 10.1002/anie.200800233] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
95 Chen MH, Lin KJ, Yang WL, Kao YW, Chen TW, Chao SC, Chang PM, Liu CY, Tzeng CH, Chao Y, Chen MH, Yeh CN, Huang CY. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer 2013;119:293-303. [PMID: 22810956 DOI: 10.1002/cncr.27743] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
96 D'Annessa I, Sattin S, Tao J, Pennati M, Sànchez-Martìn C, Moroni E, Rasola A, Zaffaroni N, Agard DA, Bernardi A, Colombo G. Design of Allosteric Stimulators of the Hsp90 ATPase as New Anticancer Leads. Chemistry 2017;23:5188-92. [PMID: 28207175 DOI: 10.1002/chem.201700169] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
97 Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, Nutting CM, Huddart RA, Harrington KJ. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One 2012;7:e35436. [PMID: 22523597 DOI: 10.1371/journal.pone.0035436] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
98 Kang Y, Taldone T, Patel HJ, Patel PD, Rodina A, Gozman A, Maharaj R, Clement CC, Patel MR, Brodsky JL, Young JC, Chiosis G. Heat shock protein 70 inhibitors. 1. 2,5'-thiodipyrimidine and 5-(phenylthio)pyrimidine acrylamides as irreversible binders to an allosteric site on heat shock protein 70. J Med Chem 2014;57:1188-207. [PMID: 24548207 DOI: 10.1021/jm401551n] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
99 Dixit A, Verkhivker GM. Probing molecular mechanisms of the Hsp90 chaperone: biophysical modeling identifies key regulators of functional dynamics. PLoS One 2012;7:e37605. [PMID: 22624053 DOI: 10.1371/journal.pone.0037605] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
100 Cui W, Aouidate A, Wang S, Yu Q, Li Y, Yuan S. Discovering Anti-Cancer Drugs via Computational Methods. Front Pharmacol 2020;11:733. [PMID: 32508653 DOI: 10.3389/fphar.2020.00733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
101 Rahimi MN, Buckton LK, Zaiter SS, Kho J, Chan V, Guo A, Konesan J, Kwon S, Lam LKO, Lawler MF, Leong M, Moldovan GD, Neale DA, Thornton G, McAlpine SR. Synthesis and Structure-Activity Relationships of Inhibitors That Target the C-Terminal MEEVD on Heat Shock Protein 90. ACS Med Chem Lett 2018;9:73-7. [PMID: 30555625 DOI: 10.1021/acsmedchemlett.7b00310] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
102 Mcnamara AV, Barclay M, Watson AJ, Jenkins JR. Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins. Biochemical Pharmacology 2012;83:355-67. [DOI: 10.1016/j.bcp.2011.11.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
103 Kubota H, Yamamoto S, Itoh E, Abe Y, Nakamura A, Izumi Y, Okada H, Iida M, Nanjo H, Itoh H, Yamamoto Y. Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma. Cell Stress Chaperones 2010;15:1003-11. [PMID: 20617406 DOI: 10.1007/s12192-010-0211-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
104 Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci 2012;103:342-9. [PMID: 22050138 DOI: 10.1111/j.1349-7006.2011.02144.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
105 Kim JG, Lee SC, Kim OH, Kim KH, Song KY, Lee SK, Choi BJ, Jeong W, Kim SJ. HSP90 inhibitor 17-DMAG exerts anticancer effects against gastric cancer cells principally by altering oxidant-antioxidant balance. Oncotarget 2017;8:56473-89. [PMID: 28915605 DOI: 10.18632/oncotarget.17007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
106 Peterson LB, Blagg BS. To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med Chem 2009;1:267-83. [PMID: 20161407 DOI: 10.4155/fmc.09.17] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
107 Shim JS, Rao R, Beebe K, Neckers L, Han I, Nahta R, Liu JO. Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir. J Natl Cancer Inst 2012;104:1576-90. [PMID: 23042933 DOI: 10.1093/jnci/djs396] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
108 Cesa LC, Shao H, Srinivasan SR, Tse E, Jain C, Zuiderweg ERP, Southworth DR, Mapp AK, Gestwicki JE. X-linked inhibitor of apoptosis protein (XIAP) is a client of heat shock protein 70 (Hsp70) and a biomarker of its inhibition. J Biol Chem 2018;293:2370-80. [PMID: 29255093 DOI: 10.1074/jbc.RA117.000634] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
109 Oromendia AB, Dodgson SE, Amon A. Aneuploidy causes proteotoxic stress in yeast. Genes Dev 2012;26:2696-708. [PMID: 23222101 DOI: 10.1101/gad.207407.112] [Cited by in Crossref: 195] [Cited by in F6Publishing: 172] [Article Influence: 19.5] [Reference Citation Analysis]
110 Jhaveri K, Modi S. HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance. Current Challenges in Personalized Cancer Medicine. Elsevier; 2012. pp. 471-517. [DOI: 10.1016/b978-0-12-397927-8.00015-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
111 Speranza G, Anderson L, Chen AP, Do K, Eugeni M, Weil M, Rubinstein L, Majerova E, Collins J, Horneffer Y, Juwara L, Zlott J, Bishop R, Conley BA, Streicher H, Tomaszewski J, Doroshow JH, Kummar S. First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile. Invest New Drugs 2018;36:230-9. [PMID: 28808818 DOI: 10.1007/s10637-017-0495-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
112 Rajani R, Gibbs CP. Treatment of Bone Tumors. Surg Pathol Clin 2012;5:301-18. [PMID: 22328909 DOI: 10.1016/j.path.2011.07.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
113 Travers J, Sharp S, Workman P. HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discovery Today 2012;17:242-52. [DOI: 10.1016/j.drudis.2011.12.021] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 8.5] [Reference Citation Analysis]
114 Wong DS, Jay DG. Emerging Roles of Extracellular Hsp90 in Cancer. Adv Cancer Res 2016;129:141-63. [PMID: 26916004 DOI: 10.1016/bs.acr.2016.01.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
115 Kopalli SR, Kang TB, Koppula S. Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents. Expert Opin Ther Pat 2016;26:1239-56. [PMID: 27568917 DOI: 10.1080/13543776.2016.1230201] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
116 Jinka S, Rachamalla HK, Bhattacharyya T, Sridharan K, Sekhar Jaggarapu MMC, Yakati V, Banerjee R. Glucocorticoid receptor-targeted liposomal delivery system for delivering small molecule ESC8 and anti-miR-Hsp90 gene construct to combat colon cancer. Biomed Mater 2021;16:024105. [PMID: 33434900 DOI: 10.1088/1748-605X/abdb08] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
117 Perego P, Cossa G, Zuco V, Zunino F. Modulation of cell sensitivity to antitumor agents by targeting survival pathways. Biochem Pharmacol 2010;80:1459-65. [PMID: 20688050 DOI: 10.1016/j.bcp.2010.07.030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
118 Ratzke C, Hellenkamp B, Hugel T. Four-colour FRET reveals directionality in the Hsp90 multicomponent machinery. Nat Commun 2014;5:4192. [PMID: 24947016 DOI: 10.1038/ncomms5192] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
119 Venkatesan N, Kanwar JR, Deepa PR, Navaneethakrishnan S, Joseph C, Krishnakumar S. Targeting HSP90/Survivin using a cell permeable structure based peptido-mimetic shepherdin in retinoblastoma. Chem Biol Interact 2016;252:141-9. [PMID: 27062892 DOI: 10.1016/j.cbi.2016.04.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
120 Ciocca DR, Arrigo AP, Calderwood SK. Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch Toxicol 2013;87:19-48. [PMID: 22885793 DOI: 10.1007/s00204-012-0918-z] [Cited by in Crossref: 168] [Cited by in F6Publishing: 161] [Article Influence: 16.8] [Reference Citation Analysis]
121 Kanugovi Vijayavittal A, Amere Subbarao S. The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism. Biochim Biophys Acta Mol Cell Res 2021;1868:118943. [PMID: 33359710 DOI: 10.1016/j.bbamcr.2020.118943] [Reference Citation Analysis]
122 Oude Munnink TH, Korte MAD, Nagengast WB, Timmer-bosscha H, Schröder CP, Jong JRD, Dongen GAV, Jensen MR, Quadt C, Hooge MNL, Vries EGD. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. European Journal of Cancer 2010;46:678-84. [DOI: 10.1016/j.ejca.2009.12.009] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
123 De Mattos-arruda L, Cortes J. Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype? The Breast 2012;21:604-7. [DOI: 10.1016/j.breast.2012.04.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
124 Miyata Y, Koren J, Kiray J, Dickey CA, Gestwicki JE. Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies. Future Med Chem 2011;3:1523-37. [PMID: 21882945 DOI: 10.4155/fmc.11.88] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
125 Mollapour M, Neckers L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta 2012;1823:648-55. [PMID: 21856339 DOI: 10.1016/j.bbamcr.2011.07.018] [Cited by in Crossref: 187] [Cited by in F6Publishing: 179] [Article Influence: 17.0] [Reference Citation Analysis]
126 Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ, Patricelli MP, Hodder P, Rosen H, Deshaies RJ. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A 2011;108:4834-9. [PMID: 21383145 DOI: 10.1073/pnas.1015312108] [Cited by in Crossref: 241] [Cited by in F6Publishing: 219] [Article Influence: 21.9] [Reference Citation Analysis]
127 Mollapour M, Neckers L. Detecting HSP90 phosphorylation. Methods Mol Biol 2011;787:67-74. [PMID: 21898227 DOI: 10.1007/978-1-61779-295-3_5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
128 Khanna C. Novel targets with potential therapeutic applications in osteosarcoma. Curr Oncol Rep 2008;10:350-8. [PMID: 18778562 DOI: 10.1007/s11912-008-0054-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
129 Astl L, Stetz G, Verkhivker GM. Dissecting Molecular Principles of the Hsp90 Chaperone Regulation by Allosteric Modulators Using a Hierarchical Simulation Approach and Network Modeling of Allosteric Interactions: Conformational Selection Dictates the Diversity of Protein Responses and Ligand-Specific Functional Mechanisms. J Chem Theory Comput 2020;16:6656-77. [PMID: 32941034 DOI: 10.1021/acs.jctc.0c00503] [Reference Citation Analysis]
130 Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross SS, Pillarsetty N, Ku T, Lewis JS, Larson SM, Levine R, Erdjument-Bromage H, Guzman ML, Nimer SD, Melnick A, Neckers L, Chiosis G. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011;7:818-26. [PMID: 21946277 DOI: 10.1038/nchembio.670] [Cited by in Crossref: 179] [Cited by in F6Publishing: 185] [Article Influence: 16.3] [Reference Citation Analysis]
131 Ghosh A, Stuehr DJ. Soluble guanylyl cyclase requires heat shock protein 90 for heme insertion during maturation of the NO-active enzyme. Proc Natl Acad Sci U S A 2012;109:12998-3003. [PMID: 22837396 DOI: 10.1073/pnas.1205854109] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
132 Zagouri F, Nonni A, Sergentanis TN, Papadimitriou CA, Michalopoulos NV, Lazaris AC, Patsouris E, Zografos GC. Heat shock protein90 in lobular neoplasia of the breast. BMC Cancer 2008;8:312. [PMID: 18957107 DOI: 10.1186/1471-2407-8-312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
133 Workman P. Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective. Adv Exp Med Biol 2020;1243:163-79. [PMID: 32297218 DOI: 10.1007/978-3-030-40204-4_11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
134 Seclì L, Fusella F, Avalle L, Brancaccio M. The dark-side of the outside: how extracellular heat shock proteins promote cancer. Cell Mol Life Sci 2021;78:4069-83. [PMID: 33544155 DOI: 10.1007/s00018-021-03764-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
135 Casale E, Amboldi N, Brasca MG, Caronni D, Colombo N, Dalvit C, Felder ER, Fogliatto G, Galvani A, Isacchi A, Polucci P, Riceputi L, Sola F, Visco C, Zuccotto F, Casuscelli F. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors. Bioorg Med Chem 2014;22:4135-50. [PMID: 24980703 DOI: 10.1016/j.bmc.2014.05.056] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
136 Hutt DM, Powers ET, Balch WE. The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Letters 2009;583:2639-46. [DOI: 10.1016/j.febslet.2009.07.014] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 4.7] [Reference Citation Analysis]
137 Liang W, Miao S, Zhang B, He S, Shou C, Manivel P, Krishna R, Chen Y, Shi YE. Synuclein γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption. Oncogene 2015;34:2398-405. [DOI: 10.1038/onc.2014.126] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
138 Tsutsumi S, Beebe K, Neckers L. Impact of heat-shock protein 90 on cancer metastasis. Future Oncol 2009;5:679-88. [PMID: 19519207 DOI: 10.2217/fon.09.30] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
139 Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, Lyerly HK. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 2012;14:R62. [PMID: 22510516 DOI: 10.1186/bcr3168] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 8.3] [Reference Citation Analysis]
140 Huang KJ, Chen YC, El-Shazly M, Du YC, Su JH, Tsao CW, Yen WH, Chang WB, Su YD, Yeh YT, Lu MC. 5-Episinuleptolide acetate, a norcembranoidal diterpene from the formosan soft coral Sinularia sp., induces leukemia cell apoptosis through Hsp90 inhibition. Molecules 2013;18:2924-33. [PMID: 23459302 DOI: 10.3390/molecules18032924] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
141 McDowell CL, Bryan Sutton R, Obermann WM. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue. Int J Biol Macromol 2009;45:310-4. [PMID: 19576239 DOI: 10.1016/j.ijbiomac.2009.06.012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
142 Ahn JH, Luo W, Kim J, Rodina A, Clement CC, Aguirre J, Sun W, Kang Y, Maharaj R, Moulick K, Zatorska D, Kokoszka M, Brodsky JL, Chiosis G. Design of a flexible cell-based assay for the evaluation of heat shock protein 70 expression modulators. Assay Drug Dev Technol 2011;9:236-46. [PMID: 21133677 DOI: 10.1089/adt.2010.0327] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
143 Sheikha GA, Al-Sha'er MA, Taha MO. Some sulfonamide drugs inhibit ATPase activity of heat shock protein 90: investigation by docking simulation and experimental validation. J Enzyme Inhib Med Chem 2011;26:603-9. [PMID: 21190426 DOI: 10.3109/14756366.2010.541394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
144 Zagouri F, Bournakis E, Koutsoukos K, Papadimitriou CA. Heat shock protein 90 (hsp90) expression and breast cancer. Pharmaceuticals (Basel) 2012;5:1008-20. [PMID: 24280702 DOI: 10.3390/ph5091008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
145 Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P. Maximizing the Therapeutic Potential of HSP90 Inhibitors. Mol Cancer Res 2015;13:1445-51. [PMID: 26219697 DOI: 10.1158/1541-7786.MCR-15-0234] [Cited by in Crossref: 114] [Cited by in F6Publishing: 71] [Article Influence: 16.3] [Reference Citation Analysis]
146 Zierer BK, Weiwad M, Rübbelke M, Freiburger L, Fischer G, Lorenz OR, Sattler M, Richter K, Buchner J. Artificial accelerators of the molecular chaperone Hsp90 facilitate rate-limiting conformational transitions. Angew Chem Int Ed Engl 2014;53:12257-62. [PMID: 25244159 DOI: 10.1002/anie.201406578] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
147 Jia Z, Liu H, Song M, Yang C, Zhao Y, Wu X, Wu Z, Zhao L. Effect of Intestinal Flora Clearance on Liver Proteomics in Mice. CP 2019;16:199-209. [DOI: 10.2174/1570164616666181115102046] [Reference Citation Analysis]
148 Razandi M, Pedram A, Levin ER. Heat shock protein 27 is required for sex steroid receptor trafficking to and functioning at the plasma membrane. Mol Cell Biol 2010;30:3249-61. [PMID: 20439495 DOI: 10.1128/MCB.01354-09] [Cited by in Crossref: 56] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
149 Ramanathan RK, Egorin MJ, Erlichman C, Remick SC, Ramalingam SS, Naret C, Holleran JL, TenEyck CJ, Ivy SP, Belani CP. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 2010;28:1520-6. [PMID: 20177028 DOI: 10.1200/JCO.2009.25.0415] [Cited by in Crossref: 66] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
150 Patel BH, Barrett AGM. Total Synthesis of Resorcinol Amide Hsp90 Inhibitor AT13387. J Org Chem 2012;77:11296-301. [DOI: 10.1021/jo302406w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
151 Zhu D, Li S, Chen C, Wang S, Zhu J, Kong L, Luo J. Tubocapsenolide A targets C-terminal cysteine residues of HSP90 to exert the anti-tumor effect. Pharmacol Res 2021;166:105523. [PMID: 33667688 DOI: 10.1016/j.phrs.2021.105523] [Reference Citation Analysis]
152 Ghaleb A, Yallowitz A, Marchenko N. Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53. Commun Biol 2019;2:436. [PMID: 31799437 DOI: 10.1038/s42003-019-0669-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
153 Barluenga S, Dakas P, Boulifa M, Moulin E, Winssinger N. Resorcylic acid lactones: A pluripotent scaffold with therapeutic potential. Comptes Rendus Chimie 2008;11:1306-17. [DOI: 10.1016/j.crci.2008.01.020] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
154 Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-60. [PMID: 20940188 DOI: 10.1200/JCO.2010.30.8338] [Cited by in Crossref: 250] [Cited by in F6Publishing: 121] [Article Influence: 20.8] [Reference Citation Analysis]
155 Suda A, Kawasaki K, Komiyama S, Isshiki Y, Yoon D, Kim S, Na Y, Hasegawa K, Fukami TA, Sato S, Miura T, Ono N, Yamazaki T, Saitoh R, Shimma N, Shiratori Y, Tsukuda T. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors. Bioorganic & Medicinal Chemistry 2014;22:892-905. [DOI: 10.1016/j.bmc.2013.11.036] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
156 Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PLoS One 2011;6:e23756. [PMID: 21858220 DOI: 10.1371/journal.pone.0023756] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
157 O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 2015;6:32774-89. [PMID: 26416415 DOI: 10.18632/oncotarget.5192] [Cited by in Crossref: 123] [Cited by in F6Publishing: 135] [Article Influence: 20.5] [Reference Citation Analysis]
158 Guarnieri MT, Blagg BS, Zhao R. A high-throughput TNP-ATP displacement assay for screening inhibitors of ATP-binding in bacterial histidine kinases. Assay Drug Dev Technol 2011;9:174-83. [PMID: 21050069 DOI: 10.1089/adt.2010.0289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
159 Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen AB, Mittlboeck M, Christensen JG, Rosen N, Solit DB, Weiser MR. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition. Clin Cancer Res 2011;17:122-33. [PMID: 21208906 DOI: 10.1158/1078-0432.CCR-10-0253] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
160 Eguchi T, Prince TL, Tran MT, Sogawa C, Lang BJ, Calderwood SK. MZF1 and SCAND1 Reciprocally Regulate CDC37 Gene Expression in Prostate Cancer. Cancers (Basel) 2019;11:E792. [PMID: 31181782 DOI: 10.3390/cancers11060792] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
161 Mayer P, Harjung A, Breinig M, Fischer L, Ehemann V, Malz M, Scherübl H, Britsch S, Werner J, Kern MA, Bläker H, Schirmacher P, Bergmann F. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors. Endocr Relat Cancer 2012;19:217-32. [PMID: 22194440 DOI: 10.1530/ERC-11-0227] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
162 Cano LQ, Lavery DN, Bevan CL. Mini-review: Foldosome regulation of androgen receptor action in prostate cancer. Mol Cell Endocrinol 2013;369:52-62. [PMID: 23395916 DOI: 10.1016/j.mce.2013.01.023] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
163 Aktug H, Acikgoz E, Uysal A, Oltulu F, Oktem G, Yigitturk G, Demir K, Yavasoglu A, Bozok Cetintas V. Comparison of cell cycle components, apoptosis and cytoskeleton-related molecules and therapeutic effects of flavopiridol and geldanamycin on the mouse fibroblast, lung cancer and embryonic stem cells. Tumor Biol 2016;37:12423-40. [DOI: 10.1007/s13277-016-5108-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
164 Perotti C, Liu R, Parusel CT, Böcher N, Schultz J, Bork P, Pfitzner E, Groner B, Shemanko CS. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res 2008;10:R94. [PMID: 19014541 DOI: 10.1186/bcr2193] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
165 Sattin S, Tao J, Vettoretti G, Moroni E, Pennati M, Lopergolo A, Morelli L, Bugatti A, Zuehlke A, Moses M, Prince T, Kijima T, Beebe K, Rusnati M, Neckers L, Zaffaroni N, Agard DA, Bernardi A, Colombo G. Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands. Chemistry 2015;21:13598-608. [PMID: 26286886 DOI: 10.1002/chem.201502211] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
166 Zhao R, Leung E, Grüner S, Schapira M, Houry WA. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One 2010;5:e9934. [PMID: 20376192 DOI: 10.1371/journal.pone.0009934] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
167 Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, Grant S. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 2008;112:793-804. [PMID: 18505786 DOI: 10.1182/blood-2007-10-116376] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
168 Laszlo A, Thotala D, Hallahan DE. Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment. Cancer J 2013;19:238-46. [PMID: 23708071 DOI: 10.1097/PPO.0b013e31829a68eb] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
169 Chen C, Zhuang Y, Chen X, Chen X, Li D, Fan Y, Xu J, Chen Y, Wu L. Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells. Oncotarget 2017;8:10025-36. [PMID: 28036294 DOI: 10.18632/oncotarget.14324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
170 Workman P, de Billy E. Putting the heat on cancer. Nat Med 2007;13:1415-7. [PMID: 18064032 DOI: 10.1038/nm1207-1415] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
171 Custodio A, Méndez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 2012;38:36-53. [PMID: 21592673 DOI: 10.1016/j.ctrv.2011.04.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
172 de Jong D, Balagué Ponz O. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy. J Pathol 2011;223:274-82. [PMID: 21125680 DOI: 10.1002/path.2807] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
173 Piper PW, Millson SH. Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges. Pharmaceuticals (Basel) 2011;4:1400-22. [PMID: 27721330 DOI: 10.3390/ph4111400] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
174 Leng A, Liu T, Yang J, Cui J, Li X, Zhu Y, Xiong T, Zhang G, Chen Y. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells. Cell Biol Int 2012;36:893-9. [DOI: 10.1042/cbi20110473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
175 Zuehlke AD, Beebe K, Neckers L, Prince T. Regulation and function of the human HSP90AA1 gene. Gene 2015;570:8-16. [PMID: 26071189 DOI: 10.1016/j.gene.2015.06.018] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 11.1] [Reference Citation Analysis]
176 Gomez CR. Role of heat shock proteins in aging and chronic inflammatory diseases. Geroscience 2021. [PMID: 34241808 DOI: 10.1007/s11357-021-00394-2] [Reference Citation Analysis]
177 Box C, Rogers SJ, Mendiola M, Eccles SA. Tumour-microenvironmental interactions: paths to progression and targets for treatment. Seminars in Cancer Biology 2010;20:128-38. [DOI: 10.1016/j.semcancer.2010.06.004] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
178 Sager RA, Woodford MR, Neckers L, Mollapour M. Detecting Posttranslational Modifications of Hsp90. Methods Mol Biol 2018;1709:209-19. [PMID: 29177662 DOI: 10.1007/978-1-4939-7477-1_16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
179 Freilich R, Arhar T, Abrams JL, Gestwicki JE. Protein-Protein Interactions in the Molecular Chaperone Network. Acc Chem Res 2018;51:940-9. [PMID: 29613769 DOI: 10.1021/acs.accounts.8b00036] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 9.8] [Reference Citation Analysis]
180 Murata T, Iwata S, Siddiquey MN, Kanazawa T, Goshima F, Kawashima D, Kimura H, Tsurumi T. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PLoS One 2013;8:e63566. [PMID: 23658841 DOI: 10.1371/journal.pone.0063566] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
181 Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008;14:250-62. [PMID: 18772114 DOI: 10.1016/j.ccr.2008.08.002] [Cited by in Crossref: 231] [Cited by in F6Publishing: 226] [Article Influence: 16.5] [Reference Citation Analysis]
182 Ferrario A, Gomer CJ. Targeting the 90 kDa heat shock protein improves photodynamic therapy. Cancer Lett 2010;289:188-94. [PMID: 19733005 DOI: 10.1016/j.canlet.2009.08.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
183 Terracciano S, Chini MG, Piaz FD, Vassallo A, Riccio R, Bruno I, Bifulco G. Dimeric and trimeric triazole based molecules as a new class of Hsp90 molecular chaperone inhibitors. European Journal of Medicinal Chemistry 2013;65:464-76. [DOI: 10.1016/j.ejmech.2013.05.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
184 Miao Z, Hu Y, Zhang X, Yang X, Tang Y, Kang A, Zhu D. Screening and identification of ligand-protein interactions using functionalized heat shock protein 90-fluorescent mesoporous silica-indium phosphide/zinc sulfide quantum dot nanocomposites. Journal of Chromatography A 2018;1562:1-11. [DOI: 10.1016/j.chroma.2018.05.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
185 Taldone T, Chiosis G. Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 2009;9:1436-46. [PMID: 19860732 DOI: 10.2174/156802609789895737] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
186 Nagaraju GP, Mezina A, Shaib WL, Landry J, El-Rayes BF. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Eur J Cancer. 2016;52:109-119. [PMID: 26682870 DOI: 10.1016/j.ejca.2015.10.057] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
187 Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2013;54:1996-2002. [PMID: 23256542 DOI: 10.3109/10428194.2012.760733] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
188 Taha EA, Ono K, Eguchi T. Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion. Int J Mol Sci 2019;20:E4588. [PMID: 31533245 DOI: 10.3390/ijms20184588] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
189 Zhang J, Liu S, Li Q, Shi Y, Wu Y, Liu F, Wang S, Zaky MY, Yousuf W, Sun Q, Guo D, Wang T, Zhang Y, Wang Y, Li M, Liu H. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer. Cell Death Differ 2020;27:2710-25. [PMID: 32327714 DOI: 10.1038/s41418-020-0538-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
190 Yang Z, Zhuang L, Szatmary P, Wen L, Sun H, Lu Y, Xu Q, Chen X. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci. 2015;12:256-263. [PMID: 25798051 DOI: 10.7150/ijms.10735] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 13.3] [Reference Citation Analysis]
191 Li QQ, Hao JJ, Zhang Z, Krane LS, Hammerich KH, Sanford T, Trepel JB, Neckers L, Agarwal PK. Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. Sci Rep 2017;7:201. [PMID: 28298630 DOI: 10.1038/s41598-017-00143-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
192 Kotha S, Sreevani G. [2 + 2 + 2] Cyclotrimerization with Propargyl Halides as Copartners: Formal Total Synthesis of the Antitumor Hsp90 Inhibitor AT13387. ACS Omega 2018;3:1850-5. [PMID: 31458497 DOI: 10.1021/acsomega.7b01976] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
193 Messaoudi S, Peyrat JF, Brion JD, Alami M. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010. Expert Opin Ther Pat 2011;21:1501-42. [PMID: 21689065 DOI: 10.1517/13543776.2011.594041] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
194 Massey AJ. ATPases as drug targets: insights from heat shock proteins 70 and 90. J Med Chem 2010;53:7280-6. [PMID: 20608738 DOI: 10.1021/jm100342z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
195 Barrett TN, Patel BH, Barrett AG. Synthesis of C-5-substituted resorcylates and resorcinamides via formylation–aromatization of functionalized keto-dioxinones. Tetrahedron 2014;70:6894-901. [DOI: 10.1016/j.tet.2014.06.099] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
196 Alarcon SV, Mollapour M, Lee MJ, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo AB, Giaccone G, Xu W, Neckers LM, Trepel JB. Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. Curr Mol Med 2012;12:1125-41. [PMID: 22804236 DOI: 10.2174/156652412803306729] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
197 Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C, Goddard J, Dunbar J, Normant E, Adams J, Grayzel D, Anderson KC, Richardson P. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma 2011;52:2308-15. [PMID: 21851215 DOI: 10.3109/10428194.2011.600481] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
198 You X, Zhang Y, Long Q, Liu Z, Feng Z, Zhang W, Teng Z, Zeng Y. Does single gene expression omnibus data mining analysis apply for only tumors and not mental illness? A preliminary study on bipolar disorder based on bioinformatics methodology. Medicine (Baltimore) 2020;99:e21989. [PMID: 32871949 DOI: 10.1097/MD.0000000000021989] [Reference Citation Analysis]
199 Millson SH, Nuttall JM, Mollapour M, Piper PW. The Hsp90/Cdc37p chaperone system is a determinant of molybdate resistance in Saccharomyces cerevisiae. Yeast 2009;26:339-47. [PMID: 19399909 DOI: 10.1002/yea.1670] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
200 Liu L, Shi B, Wang X, Xiang H. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib. Future Med Chem 2018;10:343-56. [PMID: 29347836 DOI: 10.4155/fmc-2017-0145] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
201 Ariyama J, Suyama M, Ogawa K, Ikari T, Nagaiwa J, Fujii D, Tsuchida A. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol. 1990;7:37-47. [PMID: 1964473 DOI: 10.1038/nrd2926] [Cited by in Crossref: 1691] [Cited by in F6Publishing: 1605] [Article Influence: 54.5] [Reference Citation Analysis]
202 Sawarkar R, Sievers C, Paro R. Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. Cell 2012;149:807-18. [PMID: 22579285 DOI: 10.1016/j.cell.2012.02.061] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 10.1] [Reference Citation Analysis]
203 Chang CH, Drechsel DA, Kitson RR, Siegel D, You Q, Backos DS, Ju C, Moody CJ, Ross D. 19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity. Mol Pharmacol 2014;85:849-57. [PMID: 24682466 DOI: 10.1124/mol.113.090654] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
204 Baby ST, Sharma S, Enaganti S, Cherian PR. Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors. Bioinformation 2016;12:149-55. [PMID: 28232775 DOI: 10.6026/97320630012149] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
205 He J, Niu X, Hu C, Zhang H, Guo Y, Ge Y, Wang G, Jiang Y. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening. Protein Expr Purif 2013;92:119-27. [PMID: 24056254 DOI: 10.1016/j.pep.2013.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
206 Oshima T, Masuda M. Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today 2012;42:313-27. [PMID: 22127535 DOI: 10.1007/s00595-011-0065-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
207 Buckton LK, Wang Y, Mcconnell JR, Mcalpine SR. Evaluating Dual Hsp90 and Hsp70 Inhibition as a Cancer Therapy. In: Mcalpine SR, Edkins AL, editors. Heat Shock Protein Inhibitors. Cham: Springer International Publishing; 2016. pp. 55-80. [DOI: 10.1007/7355_2015_96] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
208 Smith JR, Clarke PA, de Billy E, Workman P. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2009;28:157-69. [PMID: 18931700 DOI: 10.1038/onc.2008.380] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 6.9] [Reference Citation Analysis]
209 Horibe T, Kohno M, Haramoto M, Ohara K, Kawakami K. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med 2011;9:8. [PMID: 21235734 DOI: 10.1186/1479-5876-9-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
210 Brough PA, Barril X, Borgognoni J, Chene P, Davies NG, Davis B, Drysdale MJ, Dymock B, Eccles SA, Garcia-Echeverria C, Fromont C, Hayes A, Hubbard RE, Jordan AM, Jensen MR, Massey A, Merrett A, Padfield A, Parsons R, Radimerski T, Raynaud FI, Robertson A, Roughley SD, Schoepfer J, Simmonite H, Sharp SY, Surgenor A, Valenti M, Walls S, Webb P, Wood M, Workman P, Wright L. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 2009;52:4794-809. [PMID: 19610616 DOI: 10.1021/jm900357y] [Cited by in Crossref: 128] [Cited by in F6Publishing: 111] [Article Influence: 9.8] [Reference Citation Analysis]
211 Trentin L, Frasson M, Donella-deana A, Frezzato F, Pagano MA, Tibaldi E, Gattazzo C, Zambello R, Semenzato G, Brunati AM. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood 2008;112:4665-74. [DOI: 10.1182/blood-2008-02-139139] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
212 Prodromou C, Nuttall JM, Millson SH, Roe SM, Sim TS, Tan D, Workman P, Pearl LH, Piper PW. Structural basis of the radicicol resistance displayed by a fungal hsp90. ACS Chem Biol 2009;4:289-97. [PMID: 19236053 DOI: 10.1021/cb9000316] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
213 Karkoulis PK, Stravopodis DJ, Konstantakou EG, Voutsinas GE. Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines. Cancer Cell Int 2013;13:11. [PMID: 23394616 DOI: 10.1186/1475-2867-13-11] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
214 Schaefer S, Svenstrup TH, Guerra B. The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells. PLoS One 2017;12:e0177706. [PMID: 28542269 DOI: 10.1371/journal.pone.0177706] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
215 Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M. NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. Biomed Res Int 2015;2015:178698. [PMID: 26161387 DOI: 10.1155/2015/178698] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
216 Tillotson B, Slocum K, Coco J, Whitebread N, Thomas B, West KA, MacDougall J, Ge J, Ali JA, Palombella VJ, Normant E, Adams J, Fritz CC. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. J Biol Chem 2010;285:39835-43. [PMID: 20940293 DOI: 10.1074/jbc.M110.141580] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
217 Chen Z, Eggerman TL, Bocharov AV, Baranova IN, Vishnyakova TG, Kurlander R, Patterson AP. Heat shock proteins stimulate APOBEC-3-mediated cytidine deamination in the hepatitis B virus. J Biol Chem 2017;292:13459-79. [PMID: 28637869 DOI: 10.1074/jbc.M116.760637] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
218 Yang Y, Qi S, Shi R, Yao J, Wang L, Yuan H, Jing Y. Induction of apoptotic DNA fragmentation mediated by mitochondrial pathway with caspase-3-dependent BID cleavage in human gastric cancer cells by a new nitroxyl spin-labeled derivative of podophyllotoxin. Biomedicine & Pharmacotherapy 2017;90:131-8. [DOI: 10.1016/j.biopha.2017.03.048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
219 Barluenga S, Wang C, Fontaine J, Aouadi K, Beebe K, Tsutsumi S, Neckers L, Winssinger N. Divergent Synthesis of a Pochonin Library Targeting HSP90 and In Vivo Efficacy of an Identified Inhibitor. Angew Chem 2008;120:4504-7. [DOI: 10.1002/ange.200800233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
220 Workman P, Collins I. Probing the probes: fitness factors for small molecule tools. Chem Biol 2010;17:561-77. [PMID: 20609406 DOI: 10.1016/j.chembiol.2010.05.013] [Cited by in Crossref: 185] [Cited by in F6Publishing: 172] [Article Influence: 15.4] [Reference Citation Analysis]
221 Breinig M, Caldas-lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA. Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 2009;50:102-12. [DOI: 10.1002/hep.22912] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
222 Li W, Tsen F, Sahu D, Bhatia A, Chen M, Multhoff G, Woodley DT. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally. Int Rev Cell Mol Biol 2013;303:203-35. [PMID: 23445811 DOI: 10.1016/B978-0-12-407697-6.00005-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
223 Dai C, Dai S, Cao J. Proteotoxic stress of cancer: implication of the heat-shock response in oncogenesis. J Cell Physiol 2012;227:2982-7. [PMID: 22105155 DOI: 10.1002/jcp.24017] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]
224 Wu X, Marmarelis ME, Hodi FS. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS One 2013;8:e56134. [PMID: 23418523 DOI: 10.1371/journal.pone.0056134] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
225 Rouhi A, Miller C, Grasedieck S, Reinhart S, Stolze B, Döhner H, Kuchenbauer F, Bullinger L, Fröhling S, Scholl C. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. Oncotarget 2017;8:7678-90. [PMID: 28032595 DOI: 10.18632/oncotarget.13841] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
226 Baldelli S, Limongi D, Coni C, Ciccarone F, Ciotti M, Checconi P, Palamara AT, Ciriolo MR. BK Polyomavirus Activates HSF1 Stimulating Human Kidney Hek293 Cell Proliferation. Oxid Med Cell Longev 2021;2021:9176993. [PMID: 34845419 DOI: 10.1155/2021/9176993] [Reference Citation Analysis]
227 D'Annessa I, Raniolo S, Limongelli V, Di Marino D, Colombo G. Ligand Binding, Unbinding, and Allosteric Effects: Deciphering Small-Molecule Modulation of HSP90. J Chem Theory Comput 2019;15:6368-81. [PMID: 31538783 DOI: 10.1021/acs.jctc.9b00319] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
228 Margarucci L, Monti MC, Cassiano C, Mozzicafreddo M, Angeletti M, Riccio R, Tosco A, Casapullo A. Chemical proteomics-driven discovery of oleocanthal as an Hsp90 inhibitor. Chem Commun (Camb) 2013;49:5844-6. [PMID: 23703283 DOI: 10.1039/c3cc41858h] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
229 Dong H, Zou M, Bhatia A, Jayaprakash P, Hofman F, Ying Q, Chen M, Woodley DT, Li W. Breast Cancer MDA-MB-231 Cells Use Secreted Heat Shock Protein-90alpha (Hsp90α) to Survive a Hostile Hypoxic Environment. Sci Rep 2016;6:20605. [PMID: 26846992 DOI: 10.1038/srep20605] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
230 Shkedi A, Adkisson M, Schroeder A, Eckalbar WL, Kuo SY, Neckers L, Gestwicki JE. Inhibitor Combinations Reveal Wiring of the Proteostasis Network in Prostate Cancer Cells. J Med Chem 2021;64:14809-21. [PMID: 34606726 DOI: 10.1021/acs.jmedchem.1c01342] [Reference Citation Analysis]
231 Millson SH, Prodromou C, Piper PW. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta. Biochem Pharmacol 2010;79:1581-8. [PMID: 20138026 DOI: 10.1016/j.bcp.2010.01.031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
232 Murray CW, Carr MG, Callaghan O, Chessari G, Congreve M, Cowan S, Coyle JE, Downham R, Figueroa E, Frederickson M, Graham B, Mcmenamin R, O’brien MA, Patel S, Phillips TR, Williams G, Woodhead AJ, Woolford AJ. Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. J Med Chem 2010;53:5942-55. [DOI: 10.1021/jm100059d] [Cited by in Crossref: 139] [Cited by in F6Publishing: 124] [Article Influence: 11.6] [Reference Citation Analysis]
233 Johnston M, Geoffroy MC, Sobala A, Hay R, Hutvagner G. HSP90 protein stabilizes unloaded argonaute complexes and microscopic P-bodies in human cells. Mol Biol Cell. 2010;21:1462-1469. [PMID: 20237157 DOI: 10.1091/mbc.e09-10-0885] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 8.4] [Reference Citation Analysis]
234 Jacobs DI, Qin Q, Fu A, Chen Z, Zhou J, Zhu Y. piRNA-8041 is downregulated in human glioblastoma and suppresses tumor growth in vitro and in vivo. Oncotarget 2018;9:37616-26. [PMID: 30701019 DOI: 10.18632/oncotarget.26331] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
235 Whitesell L, Lin NU. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2012;1823:756-66. [DOI: 10.1016/j.bbamcr.2011.12.006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
236 Moroni E, Zhao H, Blagg BS, Colombo G. Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities. J Chem Inf Model 2014;54:195-208. [PMID: 24397468 DOI: 10.1021/ci4005767] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
237 Liang GH, Liu N, He MT, Yang J, Liang ZJ, Gao XJ, Rahhal AH, He QY, Zhang HT, Zha ZG. Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT/GSK-3β/β-catenin signaling. J Cell Biochem 2018;119:948-59. [PMID: 28681940 DOI: 10.1002/jcb.26260] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
238 Kung PP, Sinnema PJ, Richardson P, Hickey MJ, Gajiwala KS, Wang F, Huang B, McClellan G, Wang J, Maegley K, Bergqvist S, Mehta PP, Kania R. Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone. Bioorg Med Chem Lett 2011;21:3557-62. [PMID: 21612924 DOI: 10.1016/j.bmcl.2011.04.130] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
239 Suzuki Y, Minami M, Suzuki M, Abe K, Zenno S, Tsujimoto M, Matsumoto K, Minami Y. The Hsp90 inhibitor geldanamycin abrogates colocalization of eIF4E and eIF4E-transporter into stress granules and association of eIF4E with eIF4G. J Biol Chem 2009;284:35597-604. [PMID: 19850929 DOI: 10.1074/jbc.M109.036285] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
240 Siddiqui FA, Parkkola H, Manoharan GB, Abankwa D. Medium-Throughput Detection of Hsp90/Cdc37 Protein-Protein Interaction Inhibitors Using a Split Renilla Luciferase-Based Assay. SLAS Discov 2020;25:195-206. [PMID: 31662027 DOI: 10.1177/2472555219884033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
241 Yano A, Tsutsumi S, Soga S, Lee MJ, Trepel J, Osada H, Neckers L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci U S A 2008;105:15541-6. [PMID: 18840695 DOI: 10.1073/pnas.0805354105] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis]
242 Karthikeyan G, Zambaldo C, Barluenga S, Zoete V, Karplus M, Winssinger N. Asymmetric synthesis of pochonin E and F, revision of their proposed structure, and their conversion to potent Hsp90 inhibitors. Chemistry 2012;18:8978-86. [PMID: 22696415 DOI: 10.1002/chem.201200546] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
243 Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009;106:8368-8373. [PMID: 19416831 DOI: 10.1073/pnas.0903392106] [Cited by in Crossref: 219] [Cited by in F6Publishing: 208] [Article Influence: 16.8] [Reference Citation Analysis]
244 Liu X, Feng C, Liu J, Zhao L, Liu J, Zhang W, Liu N, Niu Y. Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer. Tumour Biol 2016;37:8027-36. [PMID: 26711786 DOI: 10.1007/s13277-015-4712-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
245 Lian H, Guan P, Tan H, Zhang X, Meng Z. Near-infrared light triggered multi-hit therapeutic nanosystem for tumor specific photothermal effect amplified signal pathway regulation and ferroptosis. Bioact Mater 2022;9:63-76. [PMID: 34820556 DOI: 10.1016/j.bioactmat.2021.07.014] [Reference Citation Analysis]
246 Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, Que NS, Taldone T, Finotti P, Stephani RA, Gewirth DT, Chiosis G. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat Chem Biol 2013;9:677-84. [PMID: 23995768 DOI: 10.1038/nchembio.1335] [Cited by in Crossref: 125] [Cited by in F6Publishing: 126] [Article Influence: 13.9] [Reference Citation Analysis]
247 Annamalai B, Liu X, Gopal U, Isaacs JS. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis. Mol Cancer Res 2009;7:1021-32. [PMID: 19567782 DOI: 10.1158/1541-7786.MCR-08-0582] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
248 Woodhead AJ, Angove H, Carr MG, Chessari G, Congreve M, Coyle JE, Cosme J, Graham B, Day PJ, Downham R, Fazal L, Feltell R, Figueroa E, Frederickson M, Lewis J, McMenamin R, Murray CW, O'Brien MA, Parra L, Patel S, Phillips T, Rees DC, Rich S, Smith DM, Trewartha G, Vinkovic M, Williams B, Woolford AJ. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 2010;53:5956-69. [PMID: 20662534 DOI: 10.1021/jm100060b] [Cited by in Crossref: 173] [Cited by in F6Publishing: 148] [Article Influence: 14.4] [Reference Citation Analysis]
249 Braga AC, Carneiro BM, Batista MN, Akinaga MM, Rahal P. Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90. Cell Stress Chaperones 2017;22:113-22. [PMID: 27858224 DOI: 10.1007/s12192-016-0747-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
250 Wang L, Fan Y, Mei H, Liu Y, Zhang L, Xu J, Huang X. Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib. Cancer Manag Res 2019;11:8937-45. [PMID: 31802936 DOI: 10.2147/CMAR.S215970] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
251 Radanyi C, Le Bras G, Bouclier C, Messaoudi S, Peyrat JF, Brion JD, Alami M, Renoir JM. Tosylcyclonovobiocic acids promote cleavage of the hsp90-associated cochaperone p23. Biochem Biophys Res Commun 2009;379:514-8. [PMID: 19118525 DOI: 10.1016/j.bbrc.2008.12.102] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
252 Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 [PMID: 30416311 DOI: 10.3748/wjg.v24.i41.4635] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
253 Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 2007;11:1587-609. [PMID: 18020980 DOI: 10.1517/14728222.11.12.1587] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
254 Den RB, Lu B. Heat shock protein 90 inhibition: rationale and clinical potential. Ther Adv Med Oncol 2012;4:211-8. [PMID: 22754594 DOI: 10.1177/1758834012445574] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
255 Molnár I, Gibson DM, Krasnoff SB. Secondary metabolites from entomopathogenic Hypocrealean fungi. Nat Prod Rep 2010;27:1241. [DOI: 10.1039/c001459c] [Cited by in Crossref: 149] [Cited by in F6Publishing: 119] [Article Influence: 12.4] [Reference Citation Analysis]
256 Sobhan PK, Seervi M, Joseph J, Chandrika BB, Varghese S, Santhoshkumar T, Radhakrishna Pillai M. Identification of heat shock protein 90 inhibitors to sensitize drug resistant side population tumor cells using a cell based assay platform. Cancer Letters 2012;317:78-88. [DOI: 10.1016/j.canlet.2011.11.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
257 Talaei S, Mellatyar H, Asadi A, Akbarzadeh A, Sheervalilou R, Zarghami N. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment. Chem Biol Drug Des 2019;93:760-86. [PMID: 30697932 DOI: 10.1111/cbdd.13486] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
258 Tessari A, Palmieri D, Di Cosimo S. Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmgenomics Pers Med. 2014;7:1-19. [PMID: 24403841 DOI: 10.2147/pgpm.s53304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
259 Li D, Li C, Li L, Chen S, Wang L, Li Q, Wang X, Lei X, Shen Z. Natural Product Kongensin A is a Non-Canonical HSP90 Inhibitor that Blocks RIP3-dependent Necroptosis. Cell Chem Biol 2016;23:257-66. [PMID: 27028885 DOI: 10.1016/j.chembiol.2015.08.018] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 11.2] [Reference Citation Analysis]
260 Calderwood SK. Molecular cochaperones: tumor growth and cancer treatment. Scientifica (Cairo) 2013;2013:217513. [PMID: 24278769 DOI: 10.1155/2013/217513] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
261 Cherfaoui B, Guo T, Sun H, Cheng W, Liu F, Jiang F, Xu X, You Q. Synthesis and evaluation of 4-(2-hydroxypropyl)piperazin-1-yl) derivatives as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry 2016;24:2423-32. [DOI: 10.1016/j.bmc.2016.03.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
262 Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2:a000109. [PMID: 20516126 DOI: 10.1101/cshperspect.a000109] [Cited by in Crossref: 331] [Cited by in F6Publishing: 335] [Article Influence: 27.6] [Reference Citation Analysis]
263 Morimoto N, Yamamoto M. Effective Permeation of Anticancer Drugs into Glioblastoma Spheroids via Conjugation with a Sulfobetaine Copolymer. Biomacromolecules 2020;21:5044-52. [PMID: 33095564 DOI: 10.1021/acs.biomac.0c01200] [Reference Citation Analysis]
264 Lang BJ, Guerrero-Giménez ME, Prince TL, Ackerman A, Bonorino C, Calderwood SK. Heat Shock Proteins Are Essential Components in Transformation and Tumor Progression: Cancer Cell Intrinsic Pathways and Beyond. Int J Mol Sci 2019;20:E4507. [PMID: 31514477 DOI: 10.3390/ijms20184507] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
265 Yan W, Zhang W, Jiang T. Oncogene addiction in gliomas: implications for molecular targeted therapy. J Exp Clin Cancer Res 2011;30:58. [PMID: 21575270 DOI: 10.1186/1756-9966-30-58] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
266 Taldone T, Rodina A, DaGama Gomes EM, Riolo M, Patel HJ, Alonso-Sabadell R, Zatorska D, Patel MR, Kishinevsky S, Chiosis G. Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes. Beilstein J Org Chem 2013;9:544-56. [PMID: 23616796 DOI: 10.3762/bjoc.9.60] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
267 Lee W, Patel JH, Lockhart AC. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs 2009;18:1351-64. [PMID: 19642951 DOI: 10.1517/13543780903179286] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
268 Schwartz H, Scroggins B, Zuehlke A, Kijima T, Beebe K, Mishra A, Neckers L, Prince T. Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas. Cell Stress Chaperones 2015;20:729-41. [PMID: 26070366 DOI: 10.1007/s12192-015-0604-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
269 Yu C, Kancha RK, Duyster J. Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations. PLoS One 2014;9:e97116. [PMID: 24849514 DOI: 10.1371/journal.pone.0097116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
270 Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012;31:537-51. [PMID: 21725353 DOI: 10.1038/onc.2011.267] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 8.8] [Reference Citation Analysis]
271 Karkoulis PK, Stravopodis DJ, Voutsinas GE. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy. Tumour Biol 2016;37:6861-73. [PMID: 26662567 DOI: 10.1007/s13277-015-4544-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
272 Shao Y, Wang B, Shi D, Miao S, Manivel P, Krishna R, Chen Y, Eric Shi Y. Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption. Mol Oncol 2014;8:1521-31. [PMID: 24998446 DOI: 10.1016/j.molonc.2014.05.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
273 Stühmer T, Chatterjee M, Grella E, Seggewiss R, Langer C, Müller S, Schoepfer J, Garcia-Echeverria C, Quadt C, Jensen MR, Einsele H, Bargou RC. Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800. Br J Haematol 2009;147:319-27. [PMID: 19686236 DOI: 10.1111/j.1365-2141.2009.07852.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
274 Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 2012;209:697-711. [PMID: 22451720 DOI: 10.1084/jem.20111910] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
275 He K, Zheng X, Zhang L, Yu J. Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax. Mol Cancer Ther 2013;12:2559-68. [PMID: 23966620 DOI: 10.1158/1535-7163.MCT-13-0284] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
276 Karayazi Atici Ö, Urbanska A, Gopinathan SG, Boutillon F, Goffin V, Shemanko CS. ATM Is Required for the Prolactin-Induced HSP90-Mediated Increase in Cellular Viability and Clonogenic Growth After DNA Damage. Endocrinology 2018;159:907-30. [DOI: 10.1210/en.2017-00652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
277 Xu Y, Zhou T, Zhou Z, Su S, Roberts SA, Montfort WR, Zeng J, Chen M, Zhang W, Lin M, Zhan J, Molnár I. Rational reprogramming of fungal polyketide first-ring cyclization. Proc Natl Acad Sci U S A 2013;110:5398-403. [PMID: 23509261 DOI: 10.1073/pnas.1301201110] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
278 Bassanini I, Parapini S, Ferrandi EE, Gabriele E, Basilico N, Taramelli D, Sparatore A. Design, Synthesis and In Vitro Investigation of Novel Basic Celastrol Carboxamides as Bio-Inspired Leishmanicidal Agents Endowed with Inhibitory Activity against Leishmania Hsp90. Biomolecules 2021;11:56. [PMID: 33466300 DOI: 10.3390/biom11010056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
279 Dunphy MPS, Pillarsetty N. The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology. Cancers (Basel) 2020;12:E2712. [PMID: 32971780 DOI: 10.3390/cancers12092712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
280 Toffalini F, Kallin A, Vandenberghe P, Pierre P, Michaux L, Cools J, Demoulin JB. The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica 2009;94:1085-93. [PMID: 19644140 DOI: 10.3324/haematol.2008.001149] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
281 Sun L, Yang S, Chi G, Jin X. Hsp90 inhibitor NMS-E973 exerts the anticancer effect against glioblastoma via induction of PUMA-mediated apoptosis. Onco Targets Ther 2018;11:1583-93. [PMID: 29593424 DOI: 10.2147/OTT.S160813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
282 Barrott JJ, Haystead TA. Hsp90, an unlikely ally in the war on cancer. FEBS J 2013;280:1381-96. [PMID: 23356585 DOI: 10.1111/febs.12147] [Cited by in Crossref: 122] [Cited by in F6Publishing: 116] [Article Influence: 13.6] [Reference Citation Analysis]
283 Xu Y, Espinosa-Artiles P, Schubert V, Xu YM, Zhang W, Lin M, Gunatilaka AA, Süssmuth R, Molnár I. Characterization of the biosynthetic genes for 10,11-dehydrocurvularin, a heat shock response-modulating anticancer fungal polyketide from Aspergillus terreus. Appl Environ Microbiol 2013;79:2038-47. [PMID: 23335766 DOI: 10.1128/AEM.03334-12] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
284 Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 2012;23:765-76. [PMID: 22824822 DOI: 10.1097/CAD.0b013e328352d292] [Cited by in Crossref: 46] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
285 Chatterjee M, Andrulis M, Stühmer T, Müller E, Hofmann C, Steinbrunn T, Heimberger T, Schraud H, Kressmann S, Einsele H, Bargou RC. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2013;98:1132-41. [PMID: 23065523 DOI: 10.3324/haematol.2012.066175] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 9.0] [Reference Citation Analysis]
286 Blacklock K, Verkhivker GM. Experimentally Guided Structural Modeling and Dynamics Analysis of Hsp90–p53 Interactions: Allosteric Regulation of the Hsp90 Chaperone by a Client Protein. J Chem Inf Model 2013;53:2962-78. [DOI: 10.1021/ci400434g] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
287 Li L, Chen NN, You QD, Xu XL. An updated patent review of anticancer Hsp90 inhibitors (2013-present). Expert Opin Ther Pat 2021;31:67-80. [PMID: 32990109 DOI: 10.1080/13543776.2021.1829595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
288 Xiong X, Wang Y, Liu C, Lu Q, Liu T, Chen G, Rao H, Luo S. Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells. Exp Cell Res 2014;326:78-89. [PMID: 24880126 DOI: 10.1016/j.yexcr.2014.05.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
289 Marrugal Á, Ferrer I, Gómez-Sánchez D, Quintanal-Villalonga Á, Pastor MD, Ojeda L, Paz-Ares L, Molina-Pinelo S. Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma. Int J Mol Sci 2021;22:2538. [PMID: 33802597 DOI: 10.3390/ijms22052538] [Reference Citation Analysis]
290 D'Annessa I, Hurwitz N, Pirota V, Beretta GL, Tinelli S, Woodford M, Freccero M, Mollapour M, Zaffaroni N, Wolfson H, Colombo G. Design of Disruptors of the Hsp90-Cdc37 Interface. Molecules 2020;25:E360. [PMID: 31952296 DOI: 10.3390/molecules25020360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
291 Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011;17:2301-13. [PMID: 21349995 DOI: 10.1158/1078-0432.CCR-10-3077] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
292 Faber S, Roepman R. Balancing the Photoreceptor Proteome: Proteostasis Network Therapeutics for Inherited Retinal Disease. Genes (Basel) 2019;10:E557. [PMID: 31344897 DOI: 10.3390/genes10080557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
293 Lachowiec J, Lemus T, Borenstein E, Queitsch C. Hsp90 promotes kinase evolution. Mol Biol Evol 2015;32:91-9. [PMID: 25246701 DOI: 10.1093/molbev/msu270] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
294 Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies. Adv Cancer Res 2012;116:199-237. [PMID: 23088872 DOI: 10.1016/B978-0-12-394387-3.00006-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
295 Mohammed SB, Bakheit MA, Ernst M, Ahmed JS, Seitzer U. Identification and Characterization of Theileria annulata Heat-Shock Protein 90 (HSP90) Isoforms. Transbound Emerg Dis 2013;60:137-49. [DOI: 10.1111/tbed.12150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
296 Wang C, Barluenga S, Koripelly GK, Fontaine JG, Chen R, Yu JC, Shen X, Chabala JC, Heck JV, Rubenstein A, Winssinger N. Synthesis of pochoxime prodrugs as potent HSP90 inhibitors. Bioorg Med Chem Lett 2009;19:3836-40. [PMID: 19410458 DOI: 10.1016/j.bmcl.2009.04.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
297 Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68:4853-61. [PMID: 18559533 DOI: 10.1158/0008-5472.CAN-07-6787] [Cited by in Crossref: 380] [Cited by in F6Publishing: 205] [Article Influence: 27.1] [Reference Citation Analysis]
298 Jhaveri K, Chandarlapaty S, Iyengar N, Morris PG, Corben AD, Patil S, Akram M, Towers R, Sakr RA, King TA, Norton L, Rosen N, Hudis C, Modi S. Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clin Breast Cancer 2016;16:276-83. [PMID: 26726007 DOI: 10.1016/j.clbc.2015.11.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
299 Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL, Christodoulou A, Saur A, Tivey T, Zapf S, Bararia D, Zimber-Strobl U, Rodig SJ, Weigert O, Weinstock DM. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood 2016;128:2517-26. [PMID: 27742706 DOI: 10.1182/blood-2016-04-711176] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
300 Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, Zhao X, Reddi AL, Nyong AM, Natarajan A, Band V, Band H. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther 2011;11:263-76. [PMID: 21088503 DOI: 10.4161/cbt.11.2.13959] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
301 Patki JM, Pawar SS. HSP90: Chaperone-me-not. Pathol Oncol Res 2013;19:631-40. [DOI: 10.1007/s12253-013-9675-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
302 Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-29. [PMID: 20393178 DOI: 10.1056/NEJMra0807082] [Cited by in Crossref: 416] [Cited by in F6Publishing: 189] [Article Influence: 34.7] [Reference Citation Analysis]
303 Wawrzynow B, Zylicz A, Zylicz M. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018;1869:161-74. [DOI: 10.1016/j.bbcan.2017.12.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
304 Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011;17:1561-70. [PMID: 21278242 DOI: 10.1158/1078-0432.CCR-10-1927] [Cited by in Crossref: 139] [Cited by in F6Publishing: 71] [Article Influence: 12.6] [Reference Citation Analysis]
305 Chatterjee S, Burns TF. Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach. Int J Mol Sci. 2017;18:E1978. [PMID: 28914774 DOI: 10.3390/ijms18091978] [Cited by in Crossref: 191] [Cited by in F6Publishing: 164] [Article Influence: 38.2] [Reference Citation Analysis]
306 Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Cancer Sci 2013;104:1346-52. [PMID: 23863134 DOI: 10.1111/cas.12237] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
307 Zhang T, Li Y, Zhu Z, Gu M, Newman B, Sun D. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells. Mol Pharm 2010;7:1576-84. [PMID: 20669973 DOI: 10.1021/mp900321a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
308 Sharp SY, Roe SM, Kazlauskas E, Cikotienė I, Workman P, Matulis D, Prodromou C. Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. PLoS One 2012;7:e44642. [PMID: 22984537 DOI: 10.1371/journal.pone.0044642] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
309 Rodina A, Patel PD, Kang Y, Patel Y, Baaklini I, Wong MJ, Taldone T, Yan P, Yang C, Maharaj R, Gozman A, Patel MR, Patel HJ, Chirico W, Erdjument-Bromage H, Talele TT, Young JC, Chiosis G. Identification of an allosteric pocket on human hsp70 reveals a mode of inhibition of this therapeutically important protein. Chem Biol 2013;20:1469-80. [PMID: 24239008 DOI: 10.1016/j.chembiol.2013.10.008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 6.9] [Reference Citation Analysis]
310 Zhao H, Kusuma BR, Blagg BS. Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity. ACS Med Chem Lett 2010;1:311-5. [PMID: 21904660 DOI: 10.1021/ml100070r] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
311 Lin Z, Peng R, Li Z, Wang Y, Lu C, Shen Y, Wang J, Shi G. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition. Int J Mol Med 2015;36:424-32. [PMID: 26059743 DOI: 10.3892/ijmm.2015.2239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
312 Lierman E, Cools J. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. Expert Rev Anticancer Ther 2009;9:1295-304. [PMID: 19761433 DOI: 10.1586/era.09.82] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
313 Guarnieri MT, Zhang L, Shen J, Zhao R. The Hsp90 inhibitor radicicol interacts with the ATP-binding pocket of bacterial sensor kinase PhoQ. J Mol Biol 2008;379:82-93. [PMID: 18440021 DOI: 10.1016/j.jmb.2008.03.036] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
314 Li Y, Zhang T, Schwartz SJ, Sun D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 2009;12:17-27. [PMID: 19179103 DOI: 10.1016/j.drup.2008.12.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 99] [Article Influence: 8.7] [Reference Citation Analysis]
315 Almhanna K. Targeted Therapy for Gastric Adenocarcinoma. Current Challenges in Personalized Cancer Medicine. Elsevier; 2012. pp. 437-70. [DOI: 10.1016/b978-0-12-397927-8.00014-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
316 Chiappori F, Merelli I, Milanesi L, Colombo G, Morra G. An atomistic view of Hsp70 allosteric crosstalk: from the nucleotide to the substrate binding domain and back. Sci Rep 2016;6:23474. [PMID: 27025773 DOI: 10.1038/srep23474] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
317 Sharp S, Jones K, Workman P. Exploiting Cancer Dependence on Molecular Chaperones. Cancer Drug Design and Discovery. Elsevier; 2014. pp. 239-74. [DOI: 10.1016/b978-0-12-396521-9.00009-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
318 Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, Garcia-Echeverria C, Chène P. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008;10:R33. [PMID: 18430202 DOI: 10.1186/bcr1996] [Cited by in Crossref: 161] [Cited by in F6Publishing: 143] [Article Influence: 11.5] [Reference Citation Analysis]
319 Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood 2013;122:2837-47. [PMID: 23943653 DOI: 10.1182/blood-2013-01-479972] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 5.8] [Reference Citation Analysis]
320 Day J, Sharp S, Rowlands M, Aherne W, Lewis W, Roe S, Prodromou C, Pearl L, Workman P, Moody C. Inhibition of Hsp90 with Resorcylic Acid Macrolactones: Synthesis and Binding Studies. Chem Eur J 2010;16:10366-72. [DOI: 10.1002/chem.201001119] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
321 Taldone T, Gomes-DaGama EM, Zong H, Sen S, Alpaugh ML, Zatorska D, Alonso-Sabadell R, Guzman ML, Chiosis G. Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy. Bioorg Med Chem Lett 2011;21:5347-52. [PMID: 21802945 DOI: 10.1016/j.bmcl.2011.07.026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
322 Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49. [PMID: 20651736 DOI: 10.1038/nrc2887] [Cited by in Crossref: 974] [Cited by in F6Publishing: 920] [Article Influence: 81.2] [Reference Citation Analysis]
323 Wu YW, Chao MW, Tu HJ, Chen LC, Hsu KC, Liou JP, Yang CR, Yen SC, HuangFu WC, Pan SL. A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo. Oncogenesis 2021;10:39. [PMID: 33986242 DOI: 10.1038/s41389-021-00331-0] [Reference Citation Analysis]
324 Sharma SK, Priya S. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease. Cell Mol Life Sci 2017;74:617-29. [PMID: 27522545 DOI: 10.1007/s00018-016-2340-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
325 Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J 3rd, Modi S, Chiosis G. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opin Investig Drugs 2014;23:611-28. [PMID: 24669860 DOI: 10.1517/13543784.2014.902442] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 14.3] [Reference Citation Analysis]
326 Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009;310:71-81. [PMID: 19616059 DOI: 10.1016/j.mce.2009.07.004] [Cited by in Crossref: 97] [Cited by in F6Publishing: 80] [Article Influence: 7.5] [Reference Citation Analysis]
327 Won Y, Yoon S, Sonn CH, Lee K, Kim Y. Nano Self-Assembly of Recombinant Human Gelatin Conjugated with α-Tocopheryl Succinate for Hsp90 Inhibitor, 17-AAG, Delivery. ACS Nano 2011;5:3839-48. [DOI: 10.1021/nn200173u] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
328 Taldone T, Gillan V, Sun W, Rodina A, Patel P, Maitland K, O'Neill K, Chiosis G, Devaney E. Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90. PLoS Negl Trop Dis 2010;4:e714. [PMID: 20559560 DOI: 10.1371/journal.pntd.0000714] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
329 Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem. 2009;284:35381-35389. [PMID: 19858214 DOI: 10.1074/jbc.m109.051532] [Cited by in Crossref: 126] [Cited by in F6Publishing: 74] [Article Influence: 10.5] [Reference Citation Analysis]
330 Calderwood SK. Heat shock proteins and cancer: intracellular chaperones or extracellular signalling ligands? Philos Trans R Soc Lond B Biol Sci. 2018;373. [PMID: 29203709 DOI: 10.1098/rstb.2016.0524] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 11.8] [Reference Citation Analysis]
331 Cowen LE, Singh SD, Köhler JR, Collins C, Zaas AK, Schell WA, Aziz H, Mylonakis E, Perfect JR, Whitesell L, Lindquist S. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 2009;106:2818-23. [PMID: 19196973 DOI: 10.1073/pnas.0813394106] [Cited by in Crossref: 256] [Cited by in F6Publishing: 244] [Article Influence: 19.7] [Reference Citation Analysis]
332 Wider D, Péli-gulli M, Briand P, Tatu U, Picard D. The complementation of yeast with human or Plasmodium falciparum Hsp90 confers differential inhibitor sensitivities. Molecular and Biochemical Parasitology 2009;164:147-52. [DOI: 10.1016/j.molbiopara.2008.12.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
333 Kawaguchi K, Saito H, Okazaki S, Nagao H. Molecular dynamics study on the free energy profile for dissociation of ADP from N-terminal domain of Hsp90. Chemical Physics Letters 2013;588:226-30. [DOI: 10.1016/j.cplett.2013.10.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
334 Luo W, Sun W, Taldone T, Rodina A, Chiosis G. Heat shock protein 90 in neurodegenerative diseases. Mol Neurodegener. 2010;5:24. [PMID: 20525284 DOI: 10.1186/1750-1326-5-24] [Cited by in Crossref: 137] [Cited by in F6Publishing: 128] [Article Influence: 11.4] [Reference Citation Analysis]
335 Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2008;8:370-4. [PMID: 18644253 DOI: 10.1016/j.coph.2008.06.015] [Cited by in Crossref: 216] [Cited by in F6Publishing: 198] [Article Influence: 15.4] [Reference Citation Analysis]
336 Vyse S, McCarthy F, Broncel M, Paul A, Wong JP, Bhamra A, Huang PH. Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. J Proteomics 2018;170:130-40. [PMID: 28842319 DOI: 10.1016/j.jprot.2017.08.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
337 Lu C, Chen H, Shan Z, Yang L. Identification of differentially expressed genes between lung adenocarcinoma and lung squamous cell carcinoma by gene expression profiling. Mol Med Rep 2016;14:1483-90. [PMID: 27356570 DOI: 10.3892/mmr.2016.5420] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
338 Huyan T, Li Q, Dong DD, Yang H, Zhang J, Huang QS, Yin DC, Shang P. Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner. Immunopharmacol Immunotoxicol 2016;38:77-86. [PMID: 26642940 DOI: 10.3109/08923973.2015.1119159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
339 Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, Pearson A, Vassal G, Workman P. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010;9:1219-33. [PMID: 20457619 DOI: 10.1158/1535-7163.MCT-09-0683] [Cited by in Crossref: 60] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
340 Li Y, Zhang T, Schwartz SJ, Sun D. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function. Nutr Cancer 2011;63:1151-9. [PMID: 21875325 DOI: 10.1080/01635581.2011.596645] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
341 Ferraro M, D’annessa I, Moroni E, Morra G, Paladino A, Rinaldi S, Compostella F, Colombo G. Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design. J Med Chem 2019;62:60-87. [DOI: 10.1021/acs.jmedchem.8b00825] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
342 Tramentozzi E, Finotti P. Effects of purine-scaffold inhibitors on HUVECs: Involvement of the purinergic pathway and interference with ATP. Implications for preventing the adverse effects of extracellular Grp94. Biochem Biophys Rep 2019;19:100661. [PMID: 31317075 DOI: 10.1016/j.bbrep.2019.100661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
343 Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-53. [PMID: 18290764 DOI: 10.1042/BJ20071640] [Cited by in F6Publishing: 170] [Reference Citation Analysis]
344 Pratt WB, Morishima Y, Gestwicki JE, Lieberman AP, Osawa Y. A model in which heat shock protein 90 targets protein-folding clefts: rationale for a new approach to neuroprotective treatment of protein folding diseases. Exp Biol Med (Maywood) 2014;239:1405-13. [PMID: 24990484 DOI: 10.1177/1535370214539444] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
345 Pagliarone AC, Castañeda ED, Santana JPP, de Oliveira CAB, Robeldo TA, Teixeira FR, Borra RC. Mitochondrial heat shock protein mortalin as potential target for therapies based on oxidative stress. Photodiagnosis Photodyn Ther 2021;34:102256. [PMID: 33737220 DOI: 10.1016/j.pdpdt.2021.102256] [Reference Citation Analysis]
346 Abdelmoaty AAA, Zhang P, Lin W, Fan YJ, Ye SN, Xu JH. C0818, a novel curcumin derivative, induces ROS-dependent cytotoxicity in human hepatocellular carcinoma cells in vitro via disruption of Hsp90 function. Acta Pharmacol Sin 2021. [PMID: 33824458 DOI: 10.1038/s41401-021-00642-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
347 Khandelwal A, Crowley VM, Blagg BSJ. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside? Med Res Rev 2016;36:92-118. [PMID: 26010985 DOI: 10.1002/med.21351] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 9.1] [Reference Citation Analysis]
348 Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget 2014;5:2372-89. [PMID: 24796583 DOI: 10.18632/oncotarget.1706] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
349 Duerfeldt AS, Peterson LB, Maynard JC, Ng CL, Eletto D, Ostrovsky O, Shinogle HE, Moore DS, Argon Y, Nicchitta CV, Blagg BS. Development of a Grp94 inhibitor. J Am Chem Soc 2012;134:9796-804. [PMID: 22642269 DOI: 10.1021/ja303477g] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 8.0] [Reference Citation Analysis]
350 Mellatyar H, Talaei S, Pilehvar-Soltanahmadi Y, Barzegar A, Akbarzadeh A, Shahabi A, Barekati-Mowahed M, Zarghami N. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art. Biomed Pharmacother 2018;102:608-17. [PMID: 29602128 DOI: 10.1016/j.biopha.2018.03.102] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
351 Neckers L, Kern A, Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem Biol 2007;14:1204-6. [PMID: 18022558 DOI: 10.1016/j.chembiol.2007.11.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]